Identification of biomarkers and mechanistic insight for upadacitinib in Crohn's disease: Serum inflammatory mediator analysis from the Phase 2b CELEST study

(1) University Hospital Leuven,Leuven,Belgium

(2) AbbVie Inc.,Worcester,United States

(3) KU Leuven,Leuven,Belgium

(4) AbbVie Inc.,Chicago,United States

(5) Istituto Clinico Humanitas,Milan,Italy



This item was part of the IBD II (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019